Blüm Holdings, Inc. | Theralese® Technologies Inc.
May 09, 06:00 AM
Blüm Holdings, Inc. (OTCQB: BLMH), a cannabis company with operations throughout California, is pleased to announce the execution of a Binding Letter of Intent with Operators Only Corporation to add three additional dispensaries to its retail portfolio. If completed, the Proposed Acquisition could represent a significant milestone in Blüm Holdings’ expansion strategy and may help solidify the Company’s position as a key player in Northern California’s retail landscape.
Operators Only owns and operates three retail stores in Sacramento, including a flagship Cookies cannabis dispensary located in downtown Sacramento, a dispensary in North Sacramento, and another in South Sacramento.
Theralase® Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs“) for the safe and effective destruction of various cancers, bacteria and viruses is pleased to announce that Dr. Michael Jewett has joined Theralase®, in the role of an independent consultant, to assist the Company in the completion of enrollment of patients in the Phase II Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) clinical study.
For more information, please visit StockDayMedia.com
Operators Only owns and operates three retail stores in Sacramento, including a flagship Cookies cannabis dispensary located in downtown Sacramento, a dispensary in North Sacramento, and another in South Sacramento.
Theralase® Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (“PDCs“) for the safe and effective destruction of various cancers, bacteria and viruses is pleased to announce that Dr. Michael Jewett has joined Theralase®, in the role of an independent consultant, to assist the Company in the completion of enrollment of patients in the Phase II Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) clinical study.
For more information, please visit StockDayMedia.com